Kodosaki Eleftheria, Bell Rosie, Sogorb-Esteve Aitana, Wiltshire Katharine, Zetterberg Henrik, Heslegrave Amanda
Department of Neurodegenerative Disease, UCL Institute of Neurology, London, United Kingdom.
UK Dementia Research Institute at UCL, London, United Kingdom.
Front Neurosci. 2024 Oct 31;18:1499458. doi: 10.3389/fnins.2024.1499458. eCollection 2024.
The role of myeloid cells (granulocytes and monocytes) in neurodegeneration and neurodegenerative disorders (NDD) is indisputable. Here we discuss the roles of myeloid cells in neurodegenerative diseases, and the recent advances in biofluid and imaging myeloid biomarker research with a focus on methods that can be used in the clinic. For this review, evidence from three neurodegenerative diseases will be included, Alzheimer's disease (AD), Parkinson's disease (PD), and multiple sclerosis (MS). We discuss the potential for these biomarkers to be used in humans with suspected NDD as prognostic, diagnostic, or monitoring tools, identify knowledge gaps in literature, and propose potential approaches to further elucidate the role of myeloid cells in neurodegeneration and better utilize myeloid biomarkers in the understanding and treatment of NDD.
髓样细胞(粒细胞和单核细胞)在神经退行性变和神经退行性疾病(NDD)中的作用是无可争议的。在此,我们讨论髓样细胞在神经退行性疾病中的作用,以及生物流体和成像髓样生物标志物研究的最新进展,重点关注可用于临床的方法。在本综述中,将纳入来自三种神经退行性疾病的证据,即阿尔茨海默病(AD)、帕金森病(PD)和多发性硬化症(MS)。我们讨论了这些生物标志物作为预后、诊断或监测工具用于疑似NDD患者的潜力,确定文献中的知识空白,并提出潜在方法以进一步阐明髓样细胞在神经退行性变中的作用,以及在理解和治疗NDD中更好地利用髓样生物标志物。